Eloxx Pharmaceuticals, Inc. ELOX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
1/9
Piotroski F — financial health
-209.7
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$6.0M | — | — | -$11.9M |
| 2024 | $6.4M | -$3.1M | — | — | -$24.3M |
| 2023 | $0 | -$17.1M | — | — | -$22.6M |
| 2022 | — | -$36.1M | — | -$31.9M | -$10.7M |
| 2021 | — | -$66.7M | — | -$35.1M | $22.4M |
| 2020 | — | -$34.6M | — | — | $10.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Domicilium Real Estate Fund III LP | 10% owner | 2026-06-10 | J | 238,422 | — |
| Domicilium Real Estate Fund III LP | 10% owner | 2026-06-10 | J | 361,578 | — |
| Domicilium Real Estate Fund III LP | 10% owner | 2026-05-27 | J | 113,636 | — |
| Coastlands Capital LP | 10% owner | 2026-05-27 | J | 1,250,000 | — |
| Aggarwal Sumit | President and CEO | 2026-02-28 | Option exercise | 260,946 | $0.15 |
| Aggarwal Sumit | President and CEO | 2026-01-24 | Option exercise | 15,000 | — |
| Rubin Steven D | director | 2026-01-24 | Option exercise | 1,875 | — |
| Aggarwal Sumit | President and CEO | 2025-09-19 | Grant | 1,000,000 | — |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -209.7 (distress)
- Working capital / assets -2.259
- Retained earnings / assets -57.036
- EBIT / assets -1.222
- Equity / liabilities -0.693
Source: SEC EDGAR filings · CIK 0001035354 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.